BAFF blockade for systemic lupus erythematosus: Will the promise be fulfilled?

Immunological Reviews

Volumn 223, Issue 1, 2008, Pages 156-174

  Ramanujam, Meera ^a   Davidson, Anne ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Autoantibodies; B cells; BAFF; SLE; Therapy; TLRs

Indexed keywords

ABATACEPT; APRIL PROTEIN; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR ANTIBODY; BELIMUMAB; CYTOKINE; HYBRID PROTEIN; INTEGRIN; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN BR3 FC; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; GENE REARRANGEMENT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; REGULATORY MECHANISM; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BLOCKING; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MYELOABLATIVE AGONISTS; SELF TOLERANCE;

EID: 47249111687     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00625.x     Document Type: Review

References (108)

1. Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006 92 : 1 69.
2. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001 2 : 764 766.
3. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006 65 (Suppl.) : iii34 iii36.
4. Thien M, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004 20 : 785 798.
5. Lesley R, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004 20 : 441 453.
6. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007 13 : 543 551.
7. Treml LS, et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007 178 : 7531 7539.
8. Groom JR, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007 204 : 1959 1971.
9. Pers JO, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005 1050 : 34 39.
10. Seyler TM, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005 115 : 3083 3092.
11. Schiffer L, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008 180 : 1938 1947.
12. Schiffer LE, et al. Lowering anti-dsDNA antibodies - what's new? Lupus 2002 11 : 885 894.
13. Myckatyn SO, Russell AS. Outcome of positive antinuclear antibodies in individuals without connective tissue disease. J Rheumatol 2003 30 : 736 739.
14. Arbuckle MR, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003 349 : 1526 1533.
15. Ehrenstein MR, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995 48 : 705 711.
16. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001 7 : 1189 1193.
17. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007 25 : 419 441.
18. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998 279 : 1052 1054.
19. Looney RJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 50 : 2580 2589.
20. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 2006 177 : 4481 4487.
21. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002 109 : 1625 1633.
22. Dorner T, Lipsky PE. Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol 2006 305 : 213 240.
23. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005 435 : 590 597.
24. Lopes-Carvalho T, Kearney JF. Marginal zone B cell physiology and disease. Curr Dir Autoimmun 2005 8 : 91 123.
25. Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 2005 26 : 425 432.
26. Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006 5 : 403 408.
27. Amano H, et al. The Yaa mutation promoting murine lupus causes defective development of marginal zone B cells. J Immunol 2003 170 : 2293 2301.
28. Fields ML, et al. The regulation and activation of lupus-associated B cells. Immunol Rev 2005 204 : 165 183.
29. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol 2007 95 : 83 110.
30. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007 19 : 327 336.
31. Gross JA, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000 404 : 995 999.
32. Bossen C, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008 111 : 1004 1012.
33. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006 18 : 263 275.
34. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006 5 : 235 246.
35. Ingold K, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005 201 : 1375 1383.
36. Bischof D, et al. Selective activation of TACI by syndecan-2. Blood 2006 107 : 3235 3242.
37. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005 17 : 282 289.
38. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006 18 : 305 317.
39. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003 21 : 231 264.
40. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003 18 : 279 288.
41. Schiemann B, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001 293 : 2111 2114.
42. Cancro MP. Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev 2004 197 : 89 101.
43. Avery DT, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003 112 : 286 297.
44. Gardam S, et al. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008 28 : 1 11.
45. Woodland RT, et al. Multiple signaling pathways promote B lymphocyte stimulator-dependent B cell growth and survival. Blood 2008 111 : 750 760.
46. Enzler T, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006 25 : 403 415.
47. Treml LS, Crowley JE, Cancro MP. BLyS receptor signatures resolve homeostatically independent compartments among naive and antigen-experienced B cells. Semin Immunol 2006 18 : 297 304.
48. O'Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004 199 : 91 98.
49. Hondowicz BD, et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol 2007 19 : 465 475.
50. Ramanujam M, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006 116 : 724 734.
51. Shulga-Morskaya S, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004 173 : 2331 2341.
52. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001 14 : 573 582.
53. Rahman ZS, Rao SP, Kalled SL, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003 198 : 1157 1169.
54. Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006 18 : 290 296.
55. Litinskiy MB, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002 3 : 822 829.
56. Bacchelli C, Buckridge S, Thrasher AJ, Gaspar HB. Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency. Clin Exp Immunol 2007 149 : 401 409.
57. Ueda Y, Liao D, Yang K, Patel A, Kelsoe G. T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells. J Immunol 2007 178 : 3593 3601.
58. Katsenelson N, Kanswal S, Puig M, Mostowski H, Verthelyi D, Akkoyunlu M. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 2007 37 : 1785 1795.
59. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004 199 : 1631 1640.
60. Salzer U, Grimbacher B. TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr Opin Allergy Clin Immunol 2005 5 : 496 503.
61. Ng LG, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004 173 : 807 817.
62. Mackay F, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999 190 : 1697 1710.
63. Sutherland AP, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005 174 : 5537 5544.
64. Gorelik L, et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004 172 : 762 766.
65. Debnath I, Roundy KM, Weis JJ, Weis JH. Analysis of the regulatory role of BAFF in controlling the expression of CD21 and CD23. Mol Immunol 2007 44 : 2388 2399.
66. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005 25 : 298 302.
67. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006 15 : 570 576.
68. Lin Z, et al. Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients. J Clin Lab Anal 2007 21 : 183 187.
69. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006 8 : R6.
70. Carter RH, et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005 52 : 3943 3954.
71. Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF. A role for BLyS in the activation of innate immune cells. Blood 2006 108 : 2687 2694.
72. Thomas MD, Srivastava B, Allman D. Regulation of peripheral B cell maturation. Cell Immunol 2006 239 : 92 102.
73. Choudhury A, Cohen PL, Eisenberg RA. Mature B cells preferentially lose tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus. J Immunol 2007 179 : 5564 5570.
74. Weisel F, Wellmann U, Winkler TH. Autoreactive B cells get activated in extrafollicular sites. Eur J Immunol 2007 37 : 3330 3333.
75. Benson MJ, Erickson LD, Gleeson MW, Noelle RJ. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol 2007 19 : 275 280.
76. Paus D, et al. Antigen recognition strength regulates the choice between exrafollicular plasma cells and germinal center B cell differentiation. J Exp Med 2006 203 : 1081 1091.
77. Herlands RA, William J, Hershberg U, Shlomchik MJ. Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur J Immunol 2007 37 : 3339 3351.
78. Phan TG, et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 2006 11 : 2419 2424.
79. Noelle RJ, Erickson LD. Determinations of B cell fate in immunity and autoimmunity. Curr Dir Autoimmun 2005 8 : 1 24.
80. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003 5 (Suppl.) : S22 S27.
81. Lin WY, et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 2007 110 : 3959 3967.
82. Hahn B, Tsao B. Antibodies to DNA. In : Wallace D, Hahn B, eds. Dubois' Lupus Erythematosus, 6th edn. Philadelphia : Lippincott, Williams and Wilkins, 2002 : 425 445.
83. Hoyer BF, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004 199 : 1577 1584.
84. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005 174 : 2499 2506.
85. Ramanujam M, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004 173 : 3524 3534.
86. Singh RR. IL-4 and many roads to lupuslike autoimmunity. Clin Immunol 2003 108 : 73 79.
87. Erickson LD, Lin LL, Duan B, Morel L, Noelle RJ. A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci USA 2003 100 : 12905 12910.
88. Hang LM, Izui S, Dixon FJ. (NZW × BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981 154 : 216 221.
89. Akkerman A, et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004 37 : 445 451.
90. Adachi Y, et al. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW × BXSB)F1 mice. Immunobiol 1998 198 : 451 464.
91. Wang BY, Cherry, El-Badri NS, Good RA. Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation. Proc Natl Acad Sci USA 1997 94 : 12065 12069.
92. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006 312 : 1669 1672.
93. Amano H, et al. Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus. Arthritis Rheum 2005 52 : 2790 2798.
94. William J, Euler C, Leadbetter E, Marshak-Rothstein A, Shlomchik MJ. Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. J Immunol 2005 174 : 6872 6878.
95. Jacobson BA, Panka DJ, Nguyen KA, Erikson J, Abbas AK, Marshak-Rothstein A. Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. Immunity 1995 3 : 509 519.
96. Liu W, et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 2004 50 : 1884 1896.
97. Ju ZL, Shi GY, Zuo JX, Zhang JW. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology 2007 120 : 281 289.
98. Jacob CO, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 2006 177 : 2671 2680.
99. Schneider P, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001 194 : 1691 1697.
100. Halpern WG, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006 91 : 586 599.
101. Vugmeyster Y, et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol 2006 168 : 476 489.
102. Stohl W, et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of Belimumab (fully human monoclonal antibody to BLys) therapy in systemic lupus erythematosus (SLE) patients. Arthritis Rheum 2007 56 : S210.
103. Stohl W, et al. Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that assocaite with therapeutic responsiveness in SLE to BLyS protein antagonism by Belimumab. Arthritis Rheum 2006 54 : S780.
104. Peano S, Ponce R, Bertolino M, Vigna E, Yu P, Visich J. Nonclinical safety, pharmocokinetics and pharmocodynamics of TACI-Ig, a soluble receptor fusion protein antagonist of BLys (B Lymphocyte Stimulator) and APRIL (A Proliferation-Inducing Ligand). Arthritis Rheum 2005 52 : S285.
105. Tak PP, et al. A Phase Ib study to investigate Atacicept (TACI-Ig) in patients with rheumatoid arthritis. ACR/ARHP Scientific Meeting (late breaking abstract), November 10-15, 2006, Washington, DC.
106. Dall'Era M, et al. Trial of Atacicept in patients with systemic lupus erythematosus (SLE). ACR/ARHP Scientific Meeting (late breaking abstract), November 11-15, 2006, Washington, DC.
107. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006 54 : 723 732.
108. Mackay M, et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 2006 203 : 2157 2164.